Logo image of PPBT

PURPLE BIOTECH LTD-ADR (PPBT) Stock Fundamental Analysis

USA - NASDAQ:PPBT - US74638P1093 - ADR

1.06 USD
+0.48 (+81.82%)
Last: 10/29/2025, 8:00:01 PM
0.88 USD
-0.18 (-16.98%)
After Hours: 10/29/2025, 8:00:01 PM
Fundamental Rating

2

PPBT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While PPBT seems to be doing ok healthwise, there are quite some concerns on its profitability. PPBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PPBT had negative earnings in the past year.
In the past year PPBT has reported a negative cash flow from operations.
PPBT had negative earnings in each of the past 5 years.
In the past 5 years PPBT always reported negative operating cash flow.
PPBT Yearly Net Income VS EBIT VS OCF VS FCFPPBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a decent Return On Assets value of -7.59%, PPBT is doing good in the industry, outperforming 71.35% of the companies in the same industry.
PPBT has a better Return On Equity (-8.16%) than 75.52% of its industry peers.
Industry RankSector Rank
ROA -7.59%
ROE -8.16%
ROIC N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
PPBT Yearly ROA, ROE, ROICPPBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PPBT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPBT Yearly Profit, Operating, Gross MarginsPPBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PPBT has been increased compared to 1 year ago.
PPBT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PPBT has been reduced compared to a year ago.
PPBT Yearly Shares OutstandingPPBT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PPBT Yearly Total Debt VS Total AssetsPPBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -3.88, we must say that PPBT is in the distress zone and has some risk of bankruptcy.
PPBT's Altman-Z score of -3.88 is in line compared to the rest of the industry. PPBT outperforms 42.19% of its industry peers.
PPBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.88
ROIC/WACCN/A
WACCN/A
PPBT Yearly LT Debt VS Equity VS FCFPPBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.88 indicates that PPBT has no problem at all paying its short term obligations.
With a Current ratio value of 2.88, PPBT perfoms like the industry average, outperforming 55.73% of the companies in the same industry.
PPBT has a Quick Ratio of 2.88. This indicates that PPBT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.88, PPBT perfoms like the industry average, outperforming 57.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
PPBT Yearly Current Assets VS Current LiabilitesPPBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.20% over the past year.
EPS 1Y (TTM)94.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PPBT Yearly Revenue VS EstimatesPPBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 200K 400K 600K 800K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PPBT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPBT Price Earnings VS Forward Price EarningsPPBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPBT Per share dataPPBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PPBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PURPLE BIOTECH LTD-ADR

NASDAQ:PPBT (10/29/2025, 8:00:01 PM)

After market: 0.88 -0.18 (-16.98%)

1.06

+0.48 (+81.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06
Earnings (Next)11-13 2025-11-13
Inst OwnersN/A
Inst Owner Change-14.82%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.57M
Revenue(TTM)N/A
Net Income(TTM)-2611000
Analysts0
Price TargetN/A
Short Float %0.7%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS3.54
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.59%
ROE -8.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -3.88
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.32%
Cap/Depr(5y)46.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y70.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.82%
OCF growth 3YN/A
OCF growth 5YN/A

PURPLE BIOTECH LTD-ADR / PPBT FAQ

Can you provide the ChartMill fundamental rating for PURPLE BIOTECH LTD-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to PPBT.


Can you provide the valuation status for PURPLE BIOTECH LTD-ADR?

ChartMill assigns a valuation rating of 0 / 10 to PURPLE BIOTECH LTD-ADR (PPBT). This can be considered as Overvalued.


How profitable is PURPLE BIOTECH LTD-ADR (PPBT) stock?

PURPLE BIOTECH LTD-ADR (PPBT) has a profitability rating of 1 / 10.